Ocular Therapeutix, Inc.
OCULOcular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for eye diseases. Founded in 2004, the company specializes in creating sustained-release drug delivery products and biologics aimed at improving treatment outcomes for ocular conditions such as glaucoma, allergy, inflammation, and corneal health.
Company News
Ocular Therapeutix (NASDAQ: OCUL) shares surged approximately 21% in premarket trading after reports indicated that Sanofi is preparing a revised and higher takeover bid for the company. Sanofi had previously offered $16 per share in September, which was rejected by Ocular's board. The potential acquisition would give Sanofi exposure to the wet a...
Ocular Therapeutix has granted inducement equity awards to eight newly hired non-executive employees, including stock options and restricted stock units representing shares of the company's common stock.
Ocular Therapeutix granted inducement equity awards to a new non-executive employee, consisting of a stock option and restricted stock unit award. The company continues to develop its retinal disease treatment pipeline, with AXPAXLI in Phase 3 clinical trials for wet age-related macular degeneration.
Ocular Therapeutix reported Q2 2025 financial results with declining revenue, increased research spending, and ongoing clinical trials for eye disease treatments. The company faces reimbursement challenges but continues to advance its pipeline, particularly the AXPAXLI ocular implant for wet AMD.
Ocular Therapeutix, a biopharmaceutical company, announced the closing of enrollment for its second registrational trial, SOL-R, evaluating AXPAXLI for the treatment of wet age-related macular degeneration. The trial is the largest retinal TKI trial to date, with plans to randomize at least 555 subjects.
